Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost

European Journal of Ophthalmology

Volumn 18, Issue 4, 2008, Pages 556-562

  Mulaney, J ^a   Sonty, S ^b   Ahmad, A ^b   Stewart, J A ^c   Stewart, William C ^c,d  

^a Central Florida Eye Associates   (United States)

^b Midwest Eye Center   (United States)

^c University of South Carolina   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dorzolamide timolol fixed combination; Latanoprost; Primary open angle glaucoma

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PLACEBO; TIMOLOL; ANTIHYPERTENSIVE AGENT; DORZOLAMIDE; PROSTAGLANDIN F; SULFONAMIDE; THIOPHENE DERIVATIVE;

AGED; ARTICLE; BLURRED VISION; BURNING SENSATION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EVENING DOSAGE; FEMALE; GALLSTONE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TEAR FLOW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; DRUG COMBINATION; DRUG EFFECT; MULTICENTER STUDY; OCULOPLETHYSMOGRAPHY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 50549101905     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800409     Document Type: Article

References (36)

1. Stewart WC, Stewart JA, Nelson LA, Kruft B. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol 2008; 18: 199-204.
2. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102: 1743-52.
3. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103: 138-47.
4. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996; 103: 126-37.
5. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1999; 77: 189-92.
6. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 17-24.
7. Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998; 82: 1249-53.
8. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106 (Suppl): S10-6.
9. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA. COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004; 82: 42-8.
10. Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003; 110: 1357-60.
11. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453-7.
12. Book SA. Essentials of Statistics. New York: McGraw Hill, 1978; 7: 222-46.
13. Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA, Stewart WC. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther 1998; 14: 129-35.
14. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh) 1987; 65: 618-21.
15. Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily vs. timolol gel in treating elevated IOP. J Glaucoma 1998; 7: 402-7.
16. Stewart WC, Sharpe ED, Harbin TS, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure. Am J Ophthalmol 2000; 129: 723-7.
17. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992; 17: 691-704.
18. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F-2-alfa-1-isopropilester in the cynomolgus monkey. Exp Eye Res 1989; 48: 707-96.
19. Gabelt BT, Kaufman PL. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49: 389-402.
20. Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ. Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol 1988; 105: 30-4.
21. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2-alpha analogue, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297-304.
22. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 131: 631-5.
23. Bayer A, Weiler W, Oeverhaus U, Skrotzki FE, Stewart WC. Xplore Observation Group. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther 2004; 20: 470-8.
24. Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112: 262-6.
25. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with openangle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-84.
26. Parrish RK, Palmberg P, Sheu WP. XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703.
27. Stewart WC. Current and Future Glaucoma Therapy. Duluth, Georgia: Ciba Vision Ophthalmics, 1997; 1-43.
28. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999; 77: 668-72.
29. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106: 1024-9.
30. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999; 127: 531-6.
31. Brubaker RF, Ingram CJ, Schoff EO, Nau CB. Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects. Ophthalmology 2000; 107: 283-7.
32. Boger WP 3rd. Short term "escape" and long term "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol 1983; 28: 235-42.
33. Camras CB, Alm A, Watson P, Stiernschantz J, Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996; 103: 1916-24.
34. Boyle JE, Ghosh K, Gieser DK, Adamsons IA, The Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998;105:1945-51.
35. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA, the Dorzolamide-Timolol Combination Study Group. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1998; 105: 1952-9.
36. Konstas AG, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressure lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology 2008; 115: 99-103.